Access the full text.
Sign up today, get DeepDyve free for 14 days.
Gridelli (2009)
Treatment of advanced non-small-cell lung cancer in the elderlyLung Cancer, 66
Studies in support of special populations: geriatrics
C. Azzoli, Sherman Baker, S. Temin, W. Pao, Timothy Aliff, J. Brahmer, David Johnson, J. Laskin, G. Masters, D. Milton, L. Nordquist, D. Pfister, S. Piantadosi, J. Schiller, Reily Smith, Thomas Smith, John Strawn, D. Trent, G. Giaccone (2009)
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
Sarah Hoffe, L. Balducci (2012)
Cancer and age: general considerations.Clinics in geriatric medicine, 28 1
T. Asmis, K. Ding, L. Seymour, F. Shepherd, N. Leighl, T. Winton, M. Whitehead, J. Spaans, B. Graham, G. Goss (2008)
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 1
R. Ansari, M. Socinski, M. Edelman, C. Belani, R. Gonin, R. Catalano, D. Marinucci, R. Comis, C. Obasaju, Ruqin Chen, M. Monberg, J. Treat (2011)
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.Critical reviews in oncology/hematology, 78 2
M. Reck, S. Popat, Niels Reinmuth, D. Ruysscher, Keith Kerr, S. Peters (2012)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 25 Suppl 3
L. Paz-Ares, F. Marinis, M. Dediu, Michael Thomas, J. Pujol, P. Bidoli, O. Molinier, T. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli (2013)
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 23
E. Quoix, G. Zalcman, J. Oster, V. Westeel, E. Pichon, A. Lavolé, J. Dauba, D. Debieuvre, P. Souquet, L. Bigay-Gamé, É. Dansin, M. Poudenx, O. Molinier, F. Vaylet, D. Moro-Sibilot, D. Herman, J. Bennouna, J. Trédaniel, A. Ducoloné, M. Lebitasy, L. Baudrin, S. Laporte, B. Milleron (2011)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialThe Lancet, 378
D. Planchard, S. Popat, K. Kerr, S. Novello, E. Smit, C. Faivre-Finn, T. Mok, M. Reck, P. Schil, M. Hellmann, S. Peters (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 29 Supplement_4
L. Paz-Ares, F. Marinis, M. Dediu, Michael Thomas, J. Pujol, P. Bidoli, O. Molinier, T. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli (2012)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.The Lancet. Oncology, 13 3
T. Ciuleanu, T. Brodowicz, C. Zielinski, J. Kim, M. Krzakowski, E. Laack, Yi-long Wu, I. Bover, StephenD. Begbie, V. Tzekova, B. Čučević, J. Pereira, S. Yang, J. Madhavan, K. Sugarman, P. Peterson, W. John, K. Krejcy, C. Belani (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyThe Lancet, 374
R. Gervais, G. Robinet, C. Clément‐Duchêne, F. Denis, C. Kouri, Philippe Martin, N. Chouaki, N. Bourayou, J. Morère (2013)
Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.Lung cancer, 80 2
P. Schnabel, E. Smit, J. Carpeño, K. Leśniewski-Kmak, J. Aerts, K. Kraaij, C. Visseren-Grul, Y. Dyachkova, K. Taipale, A. Girvan, D. Moro-Sibilot (2012)
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).Lung cancer, 78 3
C. Gridelli, T. Brodowicz, C. Langer, P. Peterson, Mominul Islam, S. Guba, P. Moore, C. Visseren-Grul, G. Scagliotti (2012)
Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.Clinical lung cancer, 13 5
G. Scagliotti, P. Parikh, J. Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. Lee, A. Mellemgaard, Keunchil Park, S. Patil, J. Rolski, T. Goksel, F. Marinis, L. Simms, K. Sugarman, D. Gandara (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
M. Knetki-Wróblewska, A. Płużański, M. Krzakowski (2011)
Treatment of advanced non-small cell lung cancer in the elderlyOncology in Clinical Practice, 7
Guideline for Industry studies in support of special populations: geriatrics. ICH-E7. [U.S. Department of Health & Human Services Web site
C. Langer, J. Manola, P. Bernardo, J. Kugler, P. Bonomi, D. Cella, David Johnson (2002)
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.Journal of the National Cancer Institute, 94 3
A. Sacher, L. Le, N. Leighl, L. Coate (2013)
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?Journal of Thoracic Oncology, 8
L. Hutchins, J. Unger, J. Crowley, C. Coltman, K. Albain (1999)
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.The New England journal of medicine, 341 27
D. Ettinger, G. Bepler, R. Bueno, Andrew Chang, Joe Chang, L. Chirieac, T. D’amico, T. Demmy, S. Feigenberg, F. Grannis, T. Jahan, M. Jahanzeb, A. Kessinger, R. Komaki, M. Kris, C. Langer, Q. Le, R. Martins, G. Otterson, F. Robert, D. Sugarbaker, D. Wood (2006)
Non-small cell lung cancer clinical practice guidelines in oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 4 6
(2013)
Patients in Europe receiving platinum-based therapies as first-line treatment: results from the FRAME observational study
A. Pallis, C. Gridelli, J. Meerbeeck, J. Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. Belani, M. Aapro (2010)
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.Annals of oncology : official journal of the European Society for Medical Oncology, 21 4
ORIGINAL ARTICLE Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study Cesare Gridelli, MD,* Filippo de Marinis, MD,† Michael Thomas, MD,‡ Kumar Prabhash, MD,§ Claude El Kouri, MD,‖ Fiona Blackhall, MD,¶ Frederique Bustin, MD,# Jean-Louis Pujol, MD,** William J. John, MD, FACP,†† Belen San Antonio, PhD,‡‡ Annamaria Zimmermann, MS,†† Nadia Chouaki, MD,§§ Carla Visseren-Grul, MD,‖‖ and Luis G. Paz-Ares, MD, PhD¶¶ males and patients with a performance status of one in the elderly Introduction: The PARAMOUNT Phase III trial showed that main- subgroup. For elderly patients, the median PFS was 6.4 months for tenance pemetrexed after pemetrexed plus cisplatin induction was pemetrexed and 3.0 months for placebo; the median OS was 13.7 well tolerated and effective for patients with advanced nonsquamous months for pemetrexed and 12.1 months for placebo. For non-elderly non–small-cell lung cancer. Approximately 17% of patients receiv- patients, the median PFS was 4.0 months for pemetrexed and 2.8 ing maintenance therapy in this study were 70 years of age or older. months for placebo; the median OS was 13.9 months for pemetrexed Here we report efficacy and safety results from the PARAMOUNT and 10.8 months for placebo. Elderly patients experienced similar study for elderly (≥70 years) and non-elderly (<70 years) patients. levels
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Jul 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.